{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:20:07Z","timestamp":1790126407143,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016922","name":"MSD Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ijantimicag.2020.106252","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:15:48Z","timestamp":1606562148000},"page":"106252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database"],"prefix":"10.1016","volume":"57","author":[{"given":"Francesca","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7014","authenticated-orcid":false,"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dusina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Bezenchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Timelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-377X","authenticated-orcid":false,"given":"Francesco","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-2623","authenticated-orcid":false,"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapaola","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1114","authenticated-orcid":false,"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106252_bib0001","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/381266","article-title":"Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial","volume":"38","author":"Wegner","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0002","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0003","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00007691-200404000-00005","article-title":"Understanding HIV-1 drug resistance","volume":"26","author":"Frenkel","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/aid.2007.0070","article-title":"Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure","volume":"24","author":"Di Giambenedetto","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0005","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0006","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0007","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1086\/425424","article-title":"Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group","volume":"190","author":"Mocroft","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/135965350200700103","article-title":"Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study","volume":"7","author":"Mocroft","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0009","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients","volume":"19","author":"Zaccarelli","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0010","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/infdis\/jit017","article-title":"Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe","volume":"207","author":"De Luca","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0011","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2334-14-398","article-title":"Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003\u20132012 decade in Italy","volume":"14","author":"Franzetti","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-4690-5-12","article-title":"The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001\u20132006) in Portugal","volume":"5","author":"Vercauteren","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0013","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cid\/ciw128","article-title":"Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-year prospective cohort analysis","volume":"62","author":"Scherrer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0014","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3851\/IMP3105","article-title":"Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution","volume":"22","author":"Gill","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0015","series-title":"EACS guidelines. Version 10.0. Brussels: EACS","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0016","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf. Accessed 18 December 2019."},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0017","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in Adults","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106252_bib0018","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jac\/dkz554","article-title":"HIV multi-drug resistance is still a relevant issue despite its dramatic drop over the years","volume":"75","author":"Armenia","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0019","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/civ400","article-title":"The irreversibility of HIV drug resistance","volume":"61","author":"Kouyos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0020","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/00002030-200012220-00007","article-title":"Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure","volume":"14","author":"Miller","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0021","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1086\/340215","article-title":"Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype","volume":"185","author":"Izopet","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0022","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1097\/00002030-199912240-00007","article-title":"Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype","volume":"13","author":"Verhofstede","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1386-6532(01)00231-1","article-title":"Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy","volume":"24","author":"Albrecht","year":"2002","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0024","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016212800618129","article-title":"HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures","volume":"10","author":"Punyacam","year":"2012","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3851\/IMP1753","article-title":"Predicting antiretroviral drug resistance from the latest or the cumulative genotype","volume":"16","author":"Garcia","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0027","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350901400217","article-title":"Historical resistance profile helps to predict salvage failure","volume":"14","author":"Zaccarelli","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0028","doi-asserted-by":"crossref","first-page":"18650","DOI":"10.7448\/IAS.16.1.18650","article-title":"The challenges of success: adolescents with perinatal HIV infection","volume":"16","author":"Mofenson","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0029","doi-asserted-by":"crossref","first-page":"21506","DOI":"10.7448\/IAS.20.4.21506","article-title":"A review of transition experiences in perinatally and behaviourally acquired HIV-1 infection; same, same but different?","volume":"20","author":"Lam","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0030","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir \u2013 effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0031","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41598-020-59775-w","article-title":"Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine","volume":"10","author":"Yasutake","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QAI.0000000000001623","article-title":"HIV drug resistance in adults receiving early vs. delayed antiretroviral therapy: HPTN 052","volume":"77","author":"Palumbo","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.aids.0000198091.70325.f4","article-title":"Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort","volume":"20","author":"Braitstein","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106252_bib0034","first-page":"656","article-title":"Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users","volume":"169","author":"Wood","year":"2003","journal-title":"CMAJ"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:54Z","timestamp":1760377074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0924857920304726"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106252","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106252"}}